COLL

Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

Peers: SUPN PCRX AMRX INDV ZVRA AYTU XERS TLPH VRTX HRTX

| Held by: IJR VTI IWM PJP AVUV PBE XPH VXF CALF IWO

Scroll to Statements

Index	RUT
Market Cap	764.15M
Enterprise Value	1.81B
Income	38.17M
Sales	815.19M
Book/sh	9.54
Cash/sh	5.30
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	423
IPO	May 07, 2015

P/E	24.80
Forward P/E	3.44
PEG	4.64
P/S	0.94
P/B	2.58
P/C	4.64
P/FCF	2.27
EV/EBITDA	5.04
EV/Sales	2.22
Quick Ratio	0.87
Current Ratio	1.01
Debt/Eq	4.07
LT Debt/Eq	3.86
Option/Short	Yes / Yes

EPS (ttm)	0.99
EPS next Y	7.16
EPS next Q	1.92
EPS this Y	0.80%
EPS next Y	-4.32%
EPS next 5Y	0.74%
EPS past 3/5Y	- 17.92%
Sales past 3/5Y	18.94% 20.28%
EPS Y/Y TTM	-34.31%
Sales Y/Y TTM	7.68%
EPS Q/Q	-28.97%
Sales Q/Q	3.33%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	5.56% 0.14%

Insider Own	1.85%
Insider Trans	-2.93%
Inst Own	133.26%
Inst Trans	-0.51%
ROA	2.06%
ROE	13.36%
ROIC	2.65%
Gross Margin	59.05%
Oper. Margin	15.43%
Profit Margin	4.68%
SMA20	3.87%
SMA50	6.97%
SMA200	-24.00%
Trades

Shs Outstand	31.07M
Shs Float	30.50M
Short Float	17.03%
Short Ratio	6.37
Short Interest	5.19M
52W High	50.79 -51.58%
52W Low	21.43 14.75%
Volatility	4.92% 3.78%
ATR (14)	0.96
RSI (14)	58.83
Beta	0.72
Rel Volume	0.37
Avg Volume	815.11K
Volume	213,697

Perf Week	3.89%
Perf Month	14.21%
Perf Quarter	-12.65%
Perf Half Y	-29.48%
Perf YTD	-46.89%
Perf Year	-45.16%
Perf 3Y	0.45%
Perf 5Y	22.22%
Perf 10Y	40.51%
Recom	1.38
Target Price	44.88
Prev Close	24.47
Price	24.59
Change %	0.49%

Consensus

Strong Buy

Avg. Price Target

$44.88

Implied Upside

+82.5%

Analysts11incl. previous ratings

Rating Distribution8 Buy · 2 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 23, 2026	Initiated	OOppenheimer	Outperform	$50	+103.3%
Sep 09, 2026	Resumed	TTruist	Buy	$49	+99.3%
Sep 09, 2026	Initiated	LLeerink Partners	Outperform	$45	+83.0%
Dec 09, 2025	Initiated	BBarclays	Overweight	$58	+135.9%
Jan 10, 2025	Upgrade	NNeedham	Hold → Buy	$46	+87.1%
Jul 30, 2024	Upgrade	HH.C. Wainwright	Neutral → Buy	$47	+91.1%
Jun 07, 2024	Upgrade	JJefferies	Hold → Buy	$41 → $44	+78.9%
May 10, 2024	Downgrade	PPiper Sandler	Overweight → Neutral	$39	+58.6%
May 10, 2024	Downgrade	NNeedham	Buy → Hold
Jan 04, 2024	Downgrade	JJefferies	Buy → Hold	$30 → $37	+50.5%
Aug 25, 2023	Reiterated	NNeedham	Buy	$35 → $36	+46.4%
May 02, 2023	Resumed	JJefferies	Buy	$30	+22.0%
Aug 08, 2022	Downgrade	HH.C. Wainwright	Buy → Neutral
Feb 15, 2022	Upgrade	CCantor Fitzgerald	Neutral → Overweight	$18 → $26	+5.7%
Aug 06, 2021	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Jan 11, 2021	Reiterated	HH.C. Wainwright	Buy	$29 → $33	+34.2%
Jul 14, 2020	Initiated	BBWS Financial	Sell	$8	-67.5%
May 27, 2020	Initiated	GGuggenheim	Neutral
Feb 19, 2020	Resumed	JJefferies	Buy	$43	+74.9%
Oct 30, 2019	Reiterated	NNeedham	Buy	$33 → $25	+1.7%

Nov-05-26 09:50AM	Collegium Beats On ADHD Strength, But Pain Erosion And Heavier Spending Keep Earnings Shrinking (Earnings Whispers) +6.29%
07:51AM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press)
07:30AM	Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance (GlobeNewswire)
Oct-29-26 08:00AM	Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts (GlobeNewswire)
Oct-28-26 01:37PM	Collegium Needs Jornay And Astaris To Outrun A Fading Nucynta Franchise (Earnings Whispers)
08:00AM	Loading…
Oct-22-26 08:00AM	Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
Oct-21-26 08:00AM	Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses (GlobeNewswire)
Oct-06-26 08:00AM	Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life (GlobeNewswire)
Sep-08-26 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-26 07:30AM	Collegium Announces $50 Million Accelerated Share Repurchase Program (GlobeNewswire) +9.53%
Aug-06-26 03:03PM	Collegium Pharmaceutical Inc (COLL) (Q2 2026) Earnings Call Highlights: ADHD Portfolio Surges ... (GuruFocus.com) -18.55%
07:57AM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press)
07:30AM	Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Jul-23-26 08:00AM	Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-20-26 08:00AM	Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston (GlobeNewswire)
08:00AM	Loading…
Jun-05-26 08:00AM	Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-27-26 08:00AM	Collegium to Participate in 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 07:31AM	Collegium Completes Acquisition of AZSTARYS from Corium Therapeutics (GlobeNewswire)
May-07-26 07:54AM	Collegium Pharmaceutical: Q1 Earnings Snapshot (Associated Press) +7.72%
07:30AM	Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Apr-23-26 08:00AM	Collegium to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-08-26 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-19-26 08:00AM	Collegium to Acquire AZSTARYS from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory (GlobeNewswire)
Mar-10-26 09:04AM	Collegium Pharmaceutical, Inc. (COLL) Surged Following Record Quarterly Results (Insider Monkey)
Mar-05-26 08:00AM	Collegium to Present New Real-World Data at PainConnect 2026 (GlobeNewswire) -5.88%
Mar-03-26 08:00AM	Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community (GlobeNewswire)
Mar-02-26 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-26 03:20PM	Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today (StockStory) -5.77%
Feb-26-26 04:13PM	Collegium Pharmaceutical Inc (COLL) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:30PM	Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Loading…
12:15PM	Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates (Zacks)
09:16AM	Collegium Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
07:53AM	Collegium Pharmaceutical: Q4 Earnings Snapshot (Associated Press Finance)
07:36AM	Collegium Pharmaceutical's (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations (StockStory)
07:30AM	Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 10:07PM	Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect (StockStory)
10:00AM	Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-23-26 08:00AM	Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical (GlobeNewswire)
Feb-19-26 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
08:15AM	Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-18-26 04:07AM	Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio (Insider Monkey)
Feb-12-26 08:00AM	Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-15-26 08:00AM	Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference (GlobeNewswire)
Jan-12-26 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks) +5.73%
Jan-08-26 08:00AM	Collegium Provides 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-05-26 09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
Dec-31-25 01:04PM	Why You Should Add Encompass Health to Your Portfolio Now (Zacks)
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
Dec-30-25 08:00AM	Collegium Announces the Closing of $980 Million Syndicated Credit Facility (GlobeNewswire)
Dec-28-25 11:01PM	2 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Dec-26-25 01:42PM	Here's Why Investors Should Hold Ensign Group Stock for Now (Zacks)
Dec-22-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? (Zacks)
Dec-18-25 11:35PM	3 Unpopular Stocks We Find Risky (StockStory)
05:12AM	Best Value Stocks to Buy for Dec. 18 (Zacks)
Dec-14-25 10:31PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Dec-11-25 11:34PM	1 Growth Stock Set to Flourishand 2 Facing Challenges (StockStory)
12:51PM	MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina (Zacks)
Dec-04-25 09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-03-25 03:45PM	Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 08:23AM	Collegium Pharma and Entegris have been highlighted as Zacks Bull and Bear of the Day (Zacks)
04:00AM	Bull of the Day: Collegium Pharmaceutical (COLL) (Zacks)
Nov-18-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 12:36AM	5 Revealing Analyst Questions From Collegium Pharmaceutical's Q3 Earnings Call (StockStory)
Nov-12-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.60%
Nov-07-25 09:50AM	COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook (StockStory)
Nov-06-25 03:25PM	Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today (StockStory) +13.42%
02:09PM	Collegium Pharmaceutical Inc (COLL) Q3 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
09:30AM	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates (Zacks)
08:09AM	Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1% (StockStory)
07:47AM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance (GlobeNewswire)
Nov-04-25 10:22PM	Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow (StockStory)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-29-25 08:00AM	Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment (GlobeNewswire)
Oct-23-25 08:00AM	Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
12:02AM	Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Oct-22-25 08:00AM	Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences (GlobeNewswire)
Oct-13-25 08:00AM	Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing (GlobeNewswire)
Oct-08-25 11:25AM	Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory (Insider Monkey)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
Sep-25-25 07:19PM	Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI (Zacks)
12:00PM	All You Need to Know About Collegium Pharmaceutical (COLL) Rating Upgrade to Strong Buy (Zacks)
Sep-24-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Sep-23-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Argenx (ARGX) This Year? (Zacks)
Sep-02-25 04:07AM	Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 (Insider Monkey)
Aug-29-25 05:07AM	Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025 (Insider Monkey)
Aug-28-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 08:00AM	Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting (GlobeNewswire)
Aug-14-25 01:34AM	The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical's Q2 Earnings Call (StockStory)
Aug-12-25 03:25AM	COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure (StockStory)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dreyer Scott	Former Officer	Sep 30 '26	Proposed Sale	22.00	27,419	603,321		Sep 30 03:52 PM
Fallon John A.	Former Director	Jul 17 '26	Proposed Sale	35.73	13,920	497,429		Jul 17 12:08 PM
Fallon John A.	Former Director	Jul 15 '26	Proposed Sale	36.32	8,095	294,010		Jul 15 04:07 PM
SANTINI GINO	Director	Jun 08 '26	Option Exercise	16.49	8,700	143,463	112,483	Jun 10 04:10 PM
Freund John Gordon	Director	May 18 '26	Sale	34.05	20	681	83,952	May 20 04:05 PM
Freund John Gordon	Director	May 15 '26	Option Exercise	16.49	8,700	143,463	88,099	May 18 04:15 PM
Freund John Gordon	Director	May 15 '26	Sale	34.54	4,127	142,547	83,972	May 18 04:15 PM
Freund John Gordon	Director	May 18 '26	Proposed Sale	34.05	30	1,022		May 18 04:07 PM
Lurker Nancy	Director	May 13 '26	Sale	35.97	4,500	161,861	18,017	May 15 04:05 PM
Freund John Gordon	Director	May 15 '26	Proposed Sale	34.54	4,127	142,547		May 15 10:51 AM
BOHLIN GAREN G	Director	May 11 '26	Option Exercise	16.49	8,700	143,463	70,959	May 13 04:05 PM
BOHLIN GAREN G	Director	May 11 '26	Sale	37.18	8,700	323,491	62,259	May 13 04:05 PM
Lurker Nancy	Director	May 13 '26	Proposed Sale	35.97	4,500	161,861		May 13 12:09 PM
BOHLIN GAREN G	Director	May 11 '26	Proposed Sale	37.18	8,700	323,491		May 11 11:38 AM
Dieter David	EVP & General Counsel	Mar 18 '26	Sale	34.92	13,976	488,099	77,071	Mar 20 05:14 PM
Dieter David	Officer	Mar 18 '26	Proposed Sale	34.92	13,976	488,099		Mar 18 04:10 PM
Dieter David	Officer	Mar 09 '26	Proposed Sale	36.65	6,224	228,110		Mar 09 10:39 AM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 03 '26	Sale	40.41	49,976	2,019,437	71,770	Mar 05 04:29 PM
Dreyer Scott	Officer	Mar 03 '26	Proposed Sale	40.41	49,976	2,019,439		Mar 03 04:10 PM
RITA BALICE-GORDON	DIRECTOR	Dec 05 '25	Proposed Sale	47.03	3,650	171,673		Dec 17 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Option Exercise	15.90	17,600	279,840	121,213	Dec 10 04:32 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Sale	48.17	17,600	847,855	103,613	Dec 10 04:32 PM
Balice-Gordon Rita J.	Director	Dec 05 '25	Sale	47.03	3,650	171,673	52,629	Dec 09 04:22 PM
Dreyer Scott	Officer	Dec 08 '25	Proposed Sale	48.17	17,600	847,855		Dec 08 04:11 PM
Fallon John A.	Director	Nov 12 '25	Option Exercise	12.41	34,853	432,578	99,487	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Sale	47.21	34,853	1,645,536	64,634	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Proposed Sale	47.21	34,853	1,645,536		Nov 12 04:29 PM

Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

CEOMr. Vikram Karnani

Executive VP & CFOMs. Colleen Tupper

Executive VPMr. David Dieter

M.D.Dr. Thomas B. Smith FAAFP

Head of Investor RelationsMr. Ian Karp M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

Collegium Pharmaceutical Inc

Upgrade your Finviz experience

All the Features.
Half the Price.